However, a positive trend was noted, with a slightly higher risk in the MASLD group (OR 1.06, 95% IC1.00–1.12) [ 25 ].
← all excerpts
The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management.
1
—
—